TEVA-SUCRALFATE 1 G
SUCRALFATE : 1 G · DIN 02045702 · TEVA CANADA LIMITED
Health Canada status: MARKETED
What is TEVA-SUCRALFATE?
TEVA-SUCRALFATE 1 G contains SUCRALFATE : 1 G. It is listed in the Health Canada Drug Product Database under DIN 02045702, held by TEVA CANADA LIMITED, supplied as TABLET for ORAL administration. Health Canada currently lists it as marketed, status dated 18-Jun-2011. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is TEVA-SUCRALFATE used for?
TEVA-SUCRALFATE (sucralfate) is indicated in the treatment of duodenal and nonmalignant gastric ulcer. TEVA-SUCRALFATE is also indicated for the prophylaxis of duodenal ulcer recurrence.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
What else is TEVA-SUCRALFATE called?
The same molecule, SUCRALFATE, is registered under other names elsewhere. Buyers and prescribers searching from outside Canada — or working from a foreign prescription or tender document — often know it by one of these:
| Name | Script | Registered in |
|---|---|---|
| ALFACAR | Latin | Morocco |
| GASTROFAIT | Latin | Bahrain |
| ULCAR | Latin | Morocco |
Names are taken from national medicine registers and published price lists. A product registered abroad is not authorized for sale in Canada unless it holds its own DIN; import is possible only through the routes Health Canada permits.
Product details and regulatory record
| DIN | 02045702 |
|---|---|
| Brand name | TEVA-SUCRALFATE |
| Generic / active ingredient | SUCRALFATE : 1 G |
| Manufacturer | TEVA CANADA LIMITED |
| Strength | 1 G |
| Dosage form | TABLET |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | A02BX02 SUCRALFATE |
| AHFS class | 56:28.32 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 18-Jun-2011 |
| Original market date | 1993-12-31 00:00:00 |
How is this product identified?
Purchase orders, customs paperwork and tender documents each ask for a different identifier, and a DIN written without its leading zeros is the single most common reason an order line fails to match. Every form Nexara accepts for this product is listed here.
| DIN (8-digit, as used in Nexara ordering) | 02045702 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2045702 |
| Brand name | TEVA-SUCRALFATE |
| Active ingredient / INN | SUCRALFATE : 1 G |
| ATC code | A02BX02 |
| ATC anatomical main group | A — Alimentary tract and metabolism |
| ATC therapeutic subgroup | A02 |
| AHFS class | 56:28.32 |
| Health Canada schedule | Prescription |
| Biosimilar biologic | No |
| Market authorization holder | TEVA CANADA LIMITED |
How is it stored and handled?
Store at 15-30°C. Unit dose strips should be stored at 15-25°C and protected from high humidity.
How is it supplied?
Bottles of 100 and 500 and in boxes of 100 as unit dose strips.
Which pack is which?
| Strength on the label | 1 G |
|---|---|
| Dosage form | TABLET |
| Route | ORAL |
| Packaging as described in the monograph | Bottles of 100 and 500 and in boxes of 100 as unit dose strips. |
| Storage | Store at 15-30°C. Unit dose strips should be stored at 15-25°C and protected from high humidity. |
One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced. Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation.
What can be used instead?
Other Canadian products sharing ATC code A02BX02 SUCRALFATE. 4 of 9 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| APO-SUCRALFATE - TAB 1G | 1 G | TABLET | APOTEX INC | MARKETED | DIN 02125250 |
| SULCRATE | 1 G | TABLET | ABBVIE CORPORATION | MARKETED | DIN 02100622 |
| SULCRATE SUSPENSION PLUS | 1 G / 5 ML | SUSPENSION | ABBVIE CORPORATION | MARKETED | DIN 02103567 |
| DOM-SUCRALFATE | 1000 MG | TABLET | DOMINION PHARMACAL | CANCELLED POST MARKET | DIN 02239912 |
| NU-SUCRALFATE - TAB 1GM | 1 G | TABLET | NU-PHARM INC | CANCELLED POST MARKET | DIN 02134829 |
| PMS-SUCRALFATE | 1 G | TABLET | PHARMASCIENCE INC | CANCELLED POST MARKET | DIN 02238209 |
| SUCRALFATE-1 - TAB 1G | 1 G | TABLET | PRO DOC LIMITEE | CANCELLED POST MARKET | DIN 02130939 |
| SULCRATE SUS 100MG/ML | 100 MG | SUSPENSION | LABS NORDIC LABORATORIES INC. - SUBSIDARY OF M.M.D.C. | CANCELLED POST MARKET | DIN 00836370 |
Who else supplies SUCRALFATE worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. SUCRALFATE appears in 14 registered pack listings across 4 markets, published on 3 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How much does SUCRALFATE cost around the world?
SUCRALFATE is listed on 5 national price registers Nexara tracks, across 29 pack listings published on 4 different price bases. What each country publishes is set out below.
| Market | What that country publishes | Brands listed | Pack listings | As of |
|---|---|---|---|---|
| United States | acquisition | 2 | 20 | 03 Sep 2026 |
| Saudi Arabia | public | 4 | 4 | 01 Sep 2026 |
| Morocco | PPV (public price) | 2 | 3 | 05 Sep 2026 |
| United Arab Emirates | public | 1 | 1 | 31 Aug 2026 |
| Bahrain | retail (max) | 1 | 1 | 01 Sep 2026 |
Why there are no figures here. These bases are not comparable. A Brazilian ex-factory ceiling, a Belgian pharmacy public price and a Japanese reimbursement rate answer three different questions, and none of them is what a product lands in Canada for. Putting them side by side would mislead in both directions, so Nexara publishes where a molecule is listed and on what basis, and quotes the delivered Canadian price per order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.